Enzalutamide Treatment in COVID-19

  • STATUS
    Recruiting
  • participants needed
    500
  • sponsor
    Andreas Josefsson
Send
Updated on 5 August 2020
See if I qualify
covid-19
enzalutamide
oral contraceptives

Summary

COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.

Details
Condition Corona Virus Infection, Covid 19
Age 50years - 100years
Treatment Enzalutamide Pill
Clinical Study IdentifierNCT04475601
SponsorAndreas Josefsson
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Positive COVID-19 test
Mild to severe symptoms of COVID-19
Hospitalization
WHO performance status 0-3
Age above or equal to 50 years
Can understand all the requirements of the study, provide informed consent, and provide authorization of use and disclosure of personal health information
Estimated expected survival of 1 year (excluding symptoms due to COVID-19)

Exclusion Criteria

Severe allergy to Enzalutamide
Pregnant or breast-feeding women
Need of immediate mechanical ventilation
Current medication includes enzalutamide treatment
Stroke or Transitory Ischemic attack in medical history
Treatment for HIV
Treatment with tamoxifen
Treatment with immunosuppressive agents
Severe immunosuppressive disease
Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants)
Previous seizure in medical history
Other serious illness or medical condition
Unstable cardiovascular disease
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

covid-19
enzalutamide
oral contraceptives

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.